Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands

European Respiratory Journal

Volumn 48, Issue 5, 2016, Pages 1420-1428

  Erkens, Connie G M ^a   Slump, Erika ^b   Verhagen, Maurits ^c   Schimmel, Henrieke ^b   Cobelens, Frank ^a,d,e   Van Den Hof, Susan ^a,d,e  

^a KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Municipal Public Health Service (GGD)   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; INFECTION RISK; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NETHERLANDS; POPULATION RISK; PRIORITY JOURNAL; REINFECTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT WITHDRAWAL; COMMUNICABLE DISEASE CONTROL; MASS SCREENING; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TIME TO TREATMENT; TUBERCULOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME-TO-TREATMENT; TUBERCULOSIS; YOUNG ADULT;

EID: 84994227151     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01157-2016     Document Type: Article

References (22)

1. Uplekar M, Weil D, Lonnroth K, et al. WHO's new End TB Strategy. Lancet 2015; 385: 1799-1801.
2. Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J 2015; 45: 928-952.
3. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46: 1563-1576.
4. Erkens CG, Slump E, Verhagen M, et al. Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. Eur Respir J 2016; 47: 1492-1501.
5. Morán-Mendoza O, Marion SA, Elwood K, et al. Risk factors for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. Int J Tuberc Lung Dis 2010; 14: 1112-1119.
6. Sloot R, Schim van der Loeff MF, Kouw PM, et al. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014; 190: 1044-1052.
7. Zellweger JP, Sotgiu G, Block M, et al. Risk assessment of tuberculosis in contacts by IFN-gamma release assays. A Tuberculosis Network European Trials Group Study. Am J Respir Crit Care Med 2015; 191: 1176-1184.
8. Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet 2014; 384: 682-690.
9. Durovni B, Saraceni V, Moulton LH, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013; 13: 852-858.
10. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1992; 145: 36-41.
11. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
12. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000; 152: 247-263.
13. Horsburgh CR Jr, O'Donnell M, Chamblee S, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med 2010; 182: 420-425.
14. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131-138.
15. Sloot R, Schim van der Loeff MF, Kouw PM, et al. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med 2014; 90: 1044-1052.
16. Sharma S, Sharma A, Kadhiravan T, et al. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013; 7: CD007545.
17. van Hest NA, Smit F, Baars HW, et al. Completeness of notification of tuberculosis in The Netherlands: how reliable is record-linkage and capture-recapture analysis? Epidemiol Infect 2007; 135: 1021-1029.
18. KNCV Tuberculosis Foundation. TBC-online. www.tbc-online.nl/eng/ziekte/index.php Date last updated: July 2015.
19. Erkens CG, de Vries G, Keizer ST, et al. The epidemiology of childhood tuberculosis in the Netherlands: still room for prevention. BMC Infect Dis 2014; 14: 295.
20. De Vries G, Riesmeijer R. Nationaal Plan Tuberculosebestrijding 2016-2020. Op weg naar eliminatie. [National Plan TB control 2016-2020. Towards Elimination.] Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2016.
21. Slump E, Erkens CGM, Van Hunen R, et al. Tuberculose in Nederland 2014. Surveillance rapport. [Tuberculosis in the Netherlands 2014. Surveillance report.] Bilthoven, Rijksinstituut voor Volksgezondheid en Milieu, 2015.
22. de Vries G, Gerritsen RF, van Burg JL, et al. Tuberculose bij asielzoekers in Nederland [Tuberculosis among asylum-seekers in the Netherlands: a descriptive study among the two largest groups of asylum-seekers]. Ned Tijdschr Geneeskd 2016; 160: D51.